Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-1.17
EPS est.
$-1.17
EPS surprise
+0.17%
1-day move
-4.42%
Xenon Pharmaceuticals reported an EPS that was slightly better than expected, but did not generate any revenue, which contributed to a stock decline of 4.42%. The lack of revenue and guidance may raise concerns among investors about the company's current performance and future prospects. The stock reaction reflects uncertainty in the market following these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.17 | $-1.20 | +0.17% |
| Revenue | $— | $1M | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative treatments for neurological disorders. With a market cap of $6 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through its research and development efforts.
Last quarter
In Q4 2025, Xenon reported an EPS of $-1.31, which was worse than the expected $-1.20. The stock reacted positively, gaining 0.77% the following day despite the miss.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+27.22%
Avg 1-day reaction
-0.54%
Analysts expect a challenging quarter with a consensus EPS of $-1.20 and minimal revenue of $1 million. The market is cautious, given the company's recent performance.
Bull case
If Xenon can exceed the EPS estimate and show stronger-than-expected revenue, it may indicate improved operational efficiency and product demand, potentially boosting investor confidence.
Bear case
Conversely, if the company misses on both EPS and revenue, it could raise concerns about its financial health and future growth prospects, leading to a negative market reaction.
Key metrics to watch
EPS
$-1.20Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.
Revenue
$1MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-1.20?
A better-than-expected EPS could signal improved cost management and operational efficiency, which is crucial for investor confidence.
Q2
What revenue figures will Xenon report, and how do they compare to the $1 million consensus?
Revenue performance is critical to understanding market demand for Xenon's products and its overall financial health.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The Street may be underestimating Xenon's potential for a positive surprise, given its history of beating EPS estimates in 75% of recent quarters.
Supporting evidence
The options market is pricing a significant move of 11.45%, indicating expectations of volatility that may not align with historical performance.
Xenon's recent operational improvements could lead to better-than-expected results, despite the cautious consensus.
Key risk
If the EPS comes in better than $-1.03, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether Xenon can maintain investor confidence amidst recent performance challenges.
Bull confirmed if
An EPS of better than $-1.03 would confirm a positive outlook for the company.
Bear confirmed if
An EPS worse than $-1.32 would indicate deeper issues within the company's operations.
What the market is pricing for the move.
Implied Move
±11.45%
Historical Avg
±1.9%
The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±9.9% while XENE has averaged ±1.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
30.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 4 of 11 (36%)
This setup has occurred 30 times across Health Care in the last 2 years. 7 of 11 (64%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.5%, with a raw directional average of +3.9% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$1.7M
45,000 sh
2 insiders
Sold
$0.00
0 sh
0 insiders
Net
$1.7M
Net buying
Most Active Insiders· 2 open-market trades
$1.1M
Net buying
Smart-money positioning from the most recent 13F filings.
Institutional
107.37%
of float
Insider
0.16%
of float
Holders
439
institutions
Top Holders· as of Jun 2026
FMR, LLC
9,647,998 sh · $351.3M
9.98%
-10.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Xenon beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may experience limited movement as investors await further clarity from management.
Miss
A miss on both EPS and revenue could lead to a decline in the stock, with historical data indicating an average drop of around 1.18%.
The lines on the call that would change the story.
$559,740.00
Net buying
Recent Transactions
Sep 30, 2026 · @ $37.38
30,000 sh
$1.1M
Sep 30, 2026 · @ $37.32
15,000 sh
$559,740.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Blackrock Inc.
7,522,482 sh · $273.9M
7.78%
33.4%
Avoro Capital Advisors LLC
5,777,777 sh · $210.4M
5.98%
Flat
Polar Capital Holdings PLC
4,570,556 sh · $166.4M
4.73%
3.8%
Driehaus Capital Management, LLC
4,418,557 sh · $160.9M
4.57%
-1.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.